Suppr超能文献

骨骼衰老。

Skeletal Aging.

机构信息

Robert and Arlene Kogod Center on Aging and Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, MN.

Robert and Arlene Kogod Center on Aging and Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, MN.

出版信息

Mayo Clin Proc. 2022 Jun;97(6):1194-1208. doi: 10.1016/j.mayocp.2022.03.011.

Abstract

Aging represents the single greatest risk factor for chronic diseases, including osteoporosis, a skeletal fragility syndrome that increases fracture risk. Optimizing bone strength throughout life reduces fracture risk. Factors critical for bone strength include nutrition, physical activity, and vitamin D status, whereas unhealthy lifestyles, illnesses, and certain medications (eg, glucocorticoids) are detrimental. Hormonal status is another important determinant of skeletal health, with sex steroid concentrations, particularly estrogen, having major effects on bone remodeling. Aging exacerbates bone loss in both sexes and results in imbalanced bone resorption relative to formation; it is associated with increased marrow adiposity, osteoblast/osteocyte apoptosis, and accumulation of senescent cells. The mechanisms underlying skeletal aging are as diverse as the factors that determine the strength (and thus fragility) of bone. This review updates our current understanding of the epidemiology, pathophysiology, and treatment of osteoporosis and provides an overview of the underlying hallmark mechanisms that drive skeletal aging.

摘要

衰老是导致骨质疏松症等慢性疾病的最大单一风险因素,骨质疏松症是一种骨骼脆弱综合征,会增加骨折风险。在整个生命周期中优化骨骼强度可以降低骨折风险。影响骨骼强度的关键因素包括营养、身体活动和维生素 D 状况,而不健康的生活方式、疾病和某些药物(如糖皮质激素)则会产生不利影响。激素状态是骨骼健康的另一个重要决定因素,性激素浓度,尤其是雌激素,对骨重塑有重大影响。衰老会加剧两性的骨质流失,导致骨吸收相对于形成失衡;它与骨髓脂肪增多、成骨细胞/骨细胞凋亡以及衰老细胞积累有关。骨骼衰老的机制与决定骨骼强度(因此易碎性)的因素一样多样化。本文综述更新了我们对骨质疏松症的流行病学、病理生理学和治疗的认识,并概述了驱动骨骼衰老的潜在标志性机制。

相似文献

1
Skeletal Aging.骨骼衰老。
Mayo Clin Proc. 2022 Jun;97(6):1194-1208. doi: 10.1016/j.mayocp.2022.03.011.
3
Unresolved issues in osteoporosis in men.男性骨质疏松症的未解决问题。
Rev Endocr Metab Disord. 2001 Jan;2(1):45-64. doi: 10.1023/a:1010054924085.
5
Musculoskeletal challenges of osteoporosis.骨质疏松症的肌肉骨骼挑战
Aging (Milano). 1998 Jun;10(3):249-62. doi: 10.1007/BF03339659.
7
Epidemiology, etiology, and diagnosis of osteoporosis.骨质疏松症的流行病学、病因学及诊断
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047.

引用本文的文献

5
Mechanobiology in cellular, molecular, and tissue adaptation.细胞、分子和组织适应性中的力学生物学
Mechanobiol Med. 2023 Aug 24;1(2):100022. doi: 10.1016/j.mbm.2023.100022. eCollection 2023 Dec.
6
Treatment Considerations for Severe Osteoporosis in Older Adults.老年人严重骨质疏松症的治疗考量
Drugs Aging. 2025 May;42(5):395-412. doi: 10.1007/s40266-025-01205-5. Epub 2025 Apr 16.

本文引用的文献

2
Secondary Osteoporosis.继发性骨质疏松症
Endocr Rev. 2022 Mar 9;43(2):240-313. doi: 10.1210/endrev/bnab028.
5
The prevention of osteoporosis and sarcopenia in older adults.老年人骨质疏松症和肌肉减少症的预防。
J Am Geriatr Soc. 2021 May;69(5):1388-1398. doi: 10.1111/jgs.17043. Epub 2021 Feb 23.
6
Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span.衰老细胞清除药物:降低衰老细胞活力以延长健康寿命。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:779-803. doi: 10.1146/annurev-pharmtox-050120-105018. Epub 2020 Sep 30.
8
Osteocyte Cellular Senescence.成骨细胞细胞衰老。
Curr Osteoporos Rep. 2020 Oct;18(5):559-567. doi: 10.1007/s11914-020-00619-x.
9
Osteoporosis: evidence for vitamin D and calcium in older people.骨质疏松症:老年人维生素 D 和钙的证据。
Drug Ther Bull. 2020 Aug;58(8):122-125. doi: 10.1136/dtb.2019.000063. Epub 2020 Jun 25.
10
Cellular senescence in age-related disorders.与年龄相关的疾病中的细胞衰老。
Transl Res. 2020 Dec;226:96-104. doi: 10.1016/j.trsl.2020.06.007. Epub 2020 Jun 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验